MSB 4.69% $1.45 mesoblast limited

CEO Itescu needs to go, page-37

  1. 5,564 Posts.
    lightbulb Created with Sketch. 443
    Who knows what to believe. 'Back door with kids', not so sure about that. It is more about an unmet need in a condition with dire consequences. Sarepta scored approval with their Muscular Dystrophy gene therapy in kids, where the efficacy dropped off after 6 years of age.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.